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Circulating tumor cells (CTCs) are routinely identified as cytokeratin (CK)-positive, epithelial 
cell adhesion molecule (EpCAM)-positive, and CD45-negative and are enriched based 
on EpCAM. However, there are a number of methodological challenges regarding both 
isolation and characterization of these rare CTCs including downregulation or absence 
of EpCAM in a variety of solid tumors leading to the omission of subpopulations of 
CTCs, difficulties in analyzing RNA and protein targets in CTCs due to the rarity of these 
cells, and low levels of targets and technological limitations of visualizing the targets 
of interest on each individual cell. Building on our previous CTC research on CD45-
based negative magnetic separation and four-color fluorescent immunocytochemical 
(ICC) staining, RNA in situ hybridization (ISH) was applied to fluorescently target mRNA 
sequences corresponding to tumor-related genes at the single CTC level. Multiple 
categories of markers are targeted including CK, human epidermal growth factor 
receptor family markers, Hedgehog pathway markers, human papillomavirus markers, 
and protein arginine methyltransferase 5. In addition, an integrated method of RNA 
ISH and fluorescent ICC staining was developed to visualize CTCs on both mRNA 
and protein levels. The robustness of the integrated co-ICC and RNA ISH staining was 
demonstrated by a series of tests on representative tumor markers of different categories. 
The integrated staining can incorporate the advantages of both RNA ISH and fluorescent 
ICC staining and provide more intense signals and more specific bindings. With this 
integrated staining methodology, distinct staining patterns were applied in this report to 
facilitate the searching and characterization of rare subgroups of CTCs. These results 
support the existence of diverse groups of CTCs at both protein and mRNA transcript 
levels and provide an analytical tool for the research on CTCs of rare subgroups.
Keywords: circulating tumor cells, negative magnetic enrichment, multiparameter analysis, integrated rna ish 
and icc staining, fluorescent labeling
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inTrODUcTiOn
Circulating tumor cells (CTCs) are tumor cells or tumor-related 
cells that are shed into human circulatory systems and areas 
associated with cancer metastasis. They have the potential 
to serve as liquid biopsy material that can provide a wealth of 
real-time information on patient disease state, treatment efficacy, 
prognosis, and potential drug targets. This is particularly helpful 
due to the challenges in obtaining serial metastasis biopsies and 
to distinguish the differences between metastasis and primary 
tumor biology. Although this idea is promising, the field has faced 
multiple challenges in the isolation and characterization of CTCs 
that have impacted the broad acceptance of the utility of these 
circulating cells (1, 2).
The most common method to identify and enumerate CTCs is 
through a positive selection by targeting the epithelial cell adhe-
sion molecule (EpCAM). However, the EpCAM-based positive 
selection brings significant challenges in using CTCs as diagnos-
tic and prognostic tumor markers, or as predictive markers for 
developing therapeutic drug targets, since more than one-third of 
patients with metastatic diseases do not have detectable CTCs by 
EpCAM-based technologies (3). In fact, a number of studies have 
shown that EpCAM-negative cells, presumably CTCs, are present 
in cancer patients (4, 5). In addition, Zhang et al. (6) showed that 
the cells of EpCAM-negative phenotype can establish tumors in 
brain and metastasize to lung in nude mice, clearly demonstrating 
the tumorigenicity of this phenotype. Furthermore, Lustberg et al. 
(7) demonstrated that the elevated level of a CD45−, EpCAM−, 
CK+ phenotype is positively correlated with a decreased overall 
survival. One hypothesis is that part of CTCs from this subset 
of the patients have undergone epithelial-to-mesenchymal 
transition (EMT), resulting in downregulation of EpCAM and 
other epithelial-associated markers. To avoid the potential bias 
associated with positive selection methods, we have developed 
our negative magnetic enrichment (NME), in which we enriched 
CTCs by removing red blood cells (RBCs) through lysis and by 
removing CD45-positive cells through magnetic labeling and 
separation (8–10).
Fluorescent immunocytochemical (ICC) staining is typically 
used to analyze CTCs with multiple tumor-related markers, 
including cytokeratin (CK), human epidermal growth factor 
receptor (HER) family markers, stem cell markers, etc. (11, 12). 
Admittedly, as ICC staining targets functional proteins, it can 
provide the most direct information with respect to the cells. 
However, ICC staining is not always definitive with respect to 
protein expression levels. For some common tumor markers, it is 
not easy to set the proper “cut-off ” to determine positive signals 
from negative ones in a CTC using ICC staining. Furthermore, 
non-specific binding, which is reported to be primarily caused by 
the binding of primary and secondary antibodies to endogenous 
Fc receptors, raises the potential of false positive ICC signals (13). 
As an alternative to ICC staining, RNA analysis is a common 
approach to provide complementary information about various 
tumor-related markers.
The prevailing way to perform mRNA-level analysis on CTCs 
is to use RT-PCR or microarray analysis on the extracted mRNA 
from the CTCs that are isolated by oncomarker-based positive 
selection (14–16). Most mRNA analysis with RT-PCR and micro-
arrays, nevertheless, can only analyze the mRNA isolated from 
CTCs in an aggregated (averaged) form without giving specific 
information about the presence of mRNA signals at a single-cell 
level. To analyze the heterogeneity of CTCs, some microchip-
based single CTC capturing devices have made it possible to 
separate out individual CTCs in fluid drops by targeting CTC 
surface markers (17, 18). Meanwhile, with the capability of cap-
turing individual CTCs, recent progress in single-cell mRNA and 
transcriptome profiling provides the transcription information 
of certain oncogenes and transcriptome library for single CTCs 
from some cancer types (19). However, the throughput of these 
cutting-edge single-cell assays is relatively low; furthermore, 
these assays do not provide information regarding the morphol-
ogy of the CTCs and the locations of certain proteins and mRNAs 
within the CTCs.
To facilitate RNA analysis of CTCs at single-cell resolu-
tion with direct visualization of targets, fluorescent in  situ 
hybridization (ISH) on mRNA is a viable alternative to RT-PCR 
or microarray analysis. RNA ISH is a visualized technique to 
fluorescently label a specific nucleic acid sequence on mRNA 
with short anti-sense nucleic acid sequences. Dynamic mRNA 
transcription and movement research shows that the quanti-
fication and timeliness of RNA ISH are adequate to track the 
appearance and the location of single mRNA molecules (20). 
Furthermore, in contrast to the use of antibodies in which the 
only information known is the name of the specific clone (not 
the actual protein sequence targeted, binding pattern, etc.), the 
probe sequence and target sequence of RNA ISH are precisely 
known and have only 20 bp oligonucleotides in the most recently 
reported versions (21, 22).
In this study, we captured CTCs by our NME methodology, 
in which the only assumption is that CTCs do not have high 
expression of CD45. The isolation procedure with our NME 
can retain most heterogeneous CTCs, including the CTCs that 
are negative in epithelial markers. Meanwhile, we established a 
method to perform integrated RNA ISH and ICC staining on 
the rare cells isolated from the blood samples of the patients 
with advanced malignancies. We tested the robustness of the 
method in various categories of tumor markers, including HER 
family markers, epithelial markers, Hedgehog pathway mark-
ers, and enzymatic markers, on cell lines and isolated CTCs 
from different tumor origins. We further incorporated RNA 
ISH staining of human papillomavirus (HPV) viral mRNA with 
the integrated RNA ISH and ICC staining of tumor markers 
in CTCs. In this study, a comprehensive analytical tool for 
heterogeneous rare CTCs was established to enrich CTCs and 
visualize them on both mRNA and protein levels with a variety 
of tested markers.
MaTerials anD MeThODs
cell culture
Breast cancer cell lines, MCF-7 (HTB-22) and BT474 (HTB-20), 
and tongue cancer cell line, SCC-4 (CRL-1624), were procured 
from ATCC. HPV-positive cell lines, SCC-47 (UM-SCC-47) 
and SCC-90 (SCC-090), were provided by Dr. Quintin Pan’s 
FigUre 1 | Workflow chart of cTc magnetic enrichment, rna ish, and fluorescent immunocytochemical staining.
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lab, Department of Otolaryngology, The Ohio State University. 
SCC-47 was originally acquired from EMD Millipore, whereas 
SCC-90 cell line was originally created by Dr. Gollin’s lab 
with previously reported source and protocol (23). Hedgehog 
pathway active cell line, T47D (HTB-133), was provided by 
Dr. Majumder’s lab, College of Medicine, The Ohio State 
University, and was originally acquired from ATCC. These 
cells were grown to mid-log phase in Dulbecco’s modified 
Eagle medium (DMEM) (Cellgro) with 10% fetal bovine serum 
(FBS) (Invitrogen) and 1% non-essential amino acid (Cellgro) 
at 37°C in 5% CO2 atmosphere. Cell lines were harvested by 
washing the adherent cells with phosphate-buffered saline (PBS) 
and subsequently incubating with Accutase (Innovative Cell 
Technologies, Inc.) for 10 min at 37°C to detach cells from the 
culture flasks. Accutase was then neutralized with the culture 
medium before pelleting the cells by centrifuging at 350 ×  g 
for 5  min. Cells were finally resuspended in culture medium 
for downstream experiments.
Patient samples and Blood collection
Patients with various metastatic solid tumor malignancies, 
older than 18  years of age, were enrolled in Institutional 
Review Board (IRB)-approved protocols that permit CTC 
characterization of blood specimens. All patients gave their 
informed consent to participate in the study. After several 
standard blood tubes were drawn for routine chemotherapy 
labs, either prior to initiation of a new line of systemic therapy 
or at progression, peripheral blood (7.8–17.7 mL) was collected 
in BD Vacutainer Heparin tubes (BD Biosciences) for CTC 
enumeration and processed within 4 h of blood collection. The 
clinical characteristics of patients are summarized in Table S1 
in Supplementary Material.
normal control Blood collection
Healthy donor blood was collected from volunteer donors after 
obtaining informed consent using an IRB-approved protocol at 
The Ohio State University Medical Center and was processed 
in the same manner as tumor patient blood samples. The pro-
tocol was approved by the Cancer Institutional Review. Source 
leukocytes (buffy coat), also as a control, were purchased from 
American Red Cross, Central-Southeast Ohio region.
sample Processing for negative Depletion 
enrichment
Blood samples were kept at ambient temperature and subjected 
to a CTC enrichment procedure within 4 h after blood collection 
using our NME approach, as described previously (24, 25). Briefly, 
blood samples were subjected to an optimized RBC lysis step 
and were labeled with anti-CD45 tetrameric antibody complex 
(TAC; Stem Cell Technologies). The cells with CD45 TAC were 
then incubated with dextran-coated magnetic nanoparticles and 
subsequently ran through the quadrupole magnetic sorter (QMS) 
system. The CD45 negative or low positive cells from the blood 
of patients or healthy donors enriched in the NME, as described 
above, is referred as NME cells in the following parts. The effec-
tiveness of NME on patient blood samples was evaluated by the 
log10 of the ratio between the total nucleated cell number before 
NME and that after NME. Figure 1 shows the overall separation 
and analysis flow chart.
Nucleated cell counts were determined prior to RBC lysis, 
after RBC lysis, and after NME. Lysis efficiency, nucleated cell log 
depletion, and total cell log depletion were used to evaluate the 
performance of the NME process. The calculation for these three 
parameters was introduced in our earlier publication (10). As pre-
viously reported, over 120 blood specimens from breast cancer 
patient have been processed with this methodology. The average 
nucleated cell log depletion, average total cell log depletion, and 
average lysis efficiency were 2.56, 5.63, and 77.0%, respectively.
rna In Situ hybridization analysis
Approximately 2  ×  104 NME cells from the blood of a 
patient or healthy donor were used for each RNA ISH slide. 
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Approximately 2 × 104 source leukocytes spiked with 5 × 103 
cells from a cancer cell line were applied on each control 
slide. Cell suspensions were spun onto superfrost plus slides 
(Fisher Scientific) and fixed by 4% paraformaldehyde for 
10 min. Subsequently, the cells were treated with QuantiGene 
ViewRNA ISH Cell Assay Kit (Affymetrix), following the 
manufacturer’s protocol. Different nucleic acid probes with 
type 1, type 4, and type 6 fluorescent labeling conjugations 
were used to detect the corresponding mRNA sequences. Here, 
type 1, type 4, and type 6 are the fluorescent probes provided 
by Affymetrix Inc., fitting the orange, green, and far red filter 
sets, respectively. The slides were then mounted with ProLong 
Gold Anti-fade Reagent with DAPI (Invitrogen) and sealed 
with nail polish.
Fluorescent immunocytochemical 
staining with rna ish
Approximately 2  ×  104 NME cells from the blood of a 
patient or healthy donor were used for each RNA ISH slide. 
Approximately 2 × 104 source leukocytes spiked with 5 × 103 
cells from a cancer cell line were applied on each control slide. 
After following the same protocol for RNA ISH analysis as 
described above without the protease-incubation and DAPI-
mounting step in the manufacturer’s protocol, cells were then 
blocked with normal serum blocking solution (NSBS) (Table 
S2 in Supplementary Material) for 30  min and washed with 
PBS for 5  min. Subsequently, one or two primary antibod-
ies from different species of hosts [e.g., human epidermal 
growth factor receptor 2 (HER2) antibody (Clone 29D8, Cell 
Signaling Tech), epidermal growth factor receptor (EGFR) 
antibody (polyclonal, Abcam), CK antibody (Clone CK3-6H5, 
Miltenyi Biotec), etc.] were diluted to 5 μg each antibody/ml 
with Normal Antibody Diluent (MP Biomedicals) and applied 
to the slides. The slides were then incubated for 30  min in 
dark at room temperature and washed three times with 1× 
PBS containing 0.5% Tween-20 (PBST). Each washing was 
approximately 5  min. The secondary antibody [e.g., Alexa 
Fluor (AF) 488 Donkey Anti-Rabbit IgG (H + L) (Molecular 
Probes), Alexa Fluor 647 Donkey Anti-Rabbit IgG (H +  L) 
(Molecular Probes), etc.] was diluted to 5 μg each antibody/
ml with PBST and applied onto the slides. The slides were 
incubated for 30  min in the dark at room temperature and 
washed three times for 5 min with PBST. The slides were then 
mounted with ProLong Gold Anti-fade Reagent with DAPI 
(Invitrogen) and sealed with nail polish.
Microscopy setting and imaging
Nikon Eclipse 80i Advance Research Microscopy system was 
employed in this research. The Nikon Eclipse 80i Advance 
Research Microscope was equipped with Nikon IntensiLight 
C-HGFi and DS-Qi1Mc digital microscope camera. Four fil-
ter sets were used to detect and filter the signals, as shown in 
Table S3 in Supplementary Material. The microscopy automatic 
stage-moving system was designed and programed in our lab to 
linearly scan and capture pictures of all cells on slides. The motors 
were from Zaber Tech (T-LSM025A) and were controlled and 
automatized by the LabVIEW (National Instruments) program 
developed in our lab.
Data acquisition
The number of nucleated cells was counted before and after 
NME. The cell suspension was diluted at 1:25 for the cells before 
enrichment and at 1:10 for the cells after enrichment with 3% 
acetic acid. The cells in acetic acid were let stand for 10  min 
before counted using Fuchs-Rosenthal hemocytometer.
The enriched and stained cells on the slides were automati-
cally counted by NIS-elements Br (Nikon Instruments Inc.) on 
DAPI channel. Gates for the cell circularity, size, and brightness 
on the nucleic acid staining were set by the NME cells from the 
buffy coat processed and stained in the same manner with the 
same protocol. The tumor-related cells that were positive on each 
tumor marker or combination of tumor markers were counted 
manually from the pictures taken by the microscopy with auto-
matic stage-moving system.
resUlTs
immunomagnetic negative Depletion of 
Patient samples
For the blood specimens from patients with solid tumors, the 
average nucleated cell log10 depletion, the average total cell log10 
depletion, and the average lysis efficiency were 2.65, 5.64, and 
80.0%, respectively. That is, an average of more than 99.78% of 
nucleated blood cells was removed by our CD45-targeted NME. 
For the blood specimens from healthy donors, the average 
nucleated cell log10 depletion, the average total cell log10 deple-
tion, and the average lysis efficiency were 2.52, 5.76, and 70.8%, 
respectively.
rna ish on her Markers
Initially, RNA ISH was tested with the probes targeting β-actin 
(ACTB), HER2, and EGFR on BT474 and SCC-4 cell lines 
[Figure  2 (1)–(10)]. The probes targeting ACTB, EGFR, and 
HER2 were designed to be able to conjugate with type 4 (Green), 
type 1 (Orange), and type 6 (Far red) fluorescent probes, respec-
tively. ACTB, a structural protein, of which mRNA is expressed 
in most human cells, is used as a housekeeping control. In the 
RNA ISH test on HER2 and EGFR [Figure  2 (1)–(10)], both 
BT474 and SCC-4 cell lines are positive for both markers, but 
more orange (type 1) dots are observed on SCC-4 cells than 
BT474 cells, while more white (type 6) dots are observed on 
BT474 cells than SCC-4 cells. These results indicate that SCC-4 
cells show higher expression level for EGFR than BT474 cells, 
while BT474 cells show higher expression level for HER2 than 
SCC-4 cells. Qualitatively, this observation is consistent with 
the common results from the fluorescent ICC staining on 
BT474 and SCC-4. Figure 2 (11)–(15) present NME cells from 
a metastatic, triple-negative breast cancer (TNBC) patient, 
stained with the same protocol and probes. The appearance of 
HER2-positive cells, despite the original TNBC (negative for 
HER2) diagnosis of the primary tumor tissue, demonstrates 
the heterogeneity of CTCs. This argument is supported by the 
FigUre 2 | rna ish test on her family markers. RNA ISH staining with DAPI, ACTB-type 4, EGFR-type 1, and HER2-type 6. (1)–(5) are BT474 cell line; 
(6)–(10) are SCC-4 cell line; (11)–(15) are the NME cells enriched from a blood specimen of a metastatic TNBC breast cancer patient.
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discordance in receptor status between primary tumors and 
CTCs or recurrent tumors in breast cancer patients as noted by 
others (26, 27).
rna ish specificity Test
A measure of the specificity of RNA ISH probes was performed 
with customized sense probes. The sense probes were designed 
with the same amplification and fluorescent reporting structures 
as these used for the specific targeting probes (namely, anti-
sense probes), but with complementary and opposite binding 
sequences. Theoretically, this sense probe should have zero 
affinity for the targeted mRNA. Figure 3 presents the RNA ISH 
staining with sense and anti-sense probes of HER2 and EGFR on 
the NME cells from healthy donor spiked with BT474 cells. Since 
BT474 cell line is positive on CK 8, 18, and 19, the cocktail of CK 
8-type 4, CK 18-type 4, and CK 19-type 4 anti-sense probes are 
added simultaneously as a positive control to ensure the proper 
probe binding and fluorescent amplification in the RNA ISH. The 
results show that blood cells do not have any positive signal, while 
BT474 cells have positive signals only with anti-sense probes for 
both HER2 and EGFR. This result verifies the high specificity of 
RNA ISH staining.
rna ish with icc staining Procedure 
establishment Based on her and 
hedgehog Pathway Markers
After the establishment of the protocol of RNA ISH test and 
the verification of specificity, the integrated RNA ISH and ICC 
staining procedure was developed to analyze different mark-
ers in the same cell at mRNA and protein levels. ICC staining 
was attempted on intracellular markers, which is usually more 
challenging as it requires additional permeabilization of the cell 
membrane that creates higher potential for non-specific bindings, 
comparing with ICC staining on surface markers. RNA ISH was 
assigned to multiple tumor markers in HER family and Hedgehog 
pathway to verify the robustness of RNA ISH. HER signaling is 
one of the most established and clinically studied pathways. And 
often, the status of ErbB receptor tyrosine kinase family, such as 
EGFR and HER2, dictates treatments for breast cancer patients. 
While the targeted therapies are very effective, patients may 
develop resistance, which results in poor outcome. Hedgehog 
signaling is a very valuable drug target in such case because the 
hedgehog molecules, such as Gli1 and Smo, are upregulated in 
endocrine-resistant tumors (28). Figure 4A presents the staining 
of DAPI, anti-CK 8, 18, 19-AF488 (ICC), EGFR-type 1 (RNA 
ISH), and HER2-type 6 (RNA ISH) on BT474 cells. Figure 4B 
is the same combination of staining applied to NME cells from a 
metastatic colon cancer patient. Figure 5A presents the staining 
of DAPI, CK 8, 18, 19-type 4, Smo-type 1, and Gli1-type 6 on 
T47D cells. Figure  5B is the staining of DAPI, anti-CK 8, 18, 
19-AF488 (ICC), Smo-type 1, and Gli1-type 6 on the NME cells 
from a metastatic breast cancer patient. This results demonstrate 
not only the successful establishment of integrated RNA ISH and 
ICC staining on cell lines and patient-derived CTCs but also an 
evidence that the procedure can track markers from two major 
tumor signaling pathways (HER and Hedgehog) that are involved 
in many cancers.
rna ish with icc  
staining – consistency Test
To further verify the robustness of the integrated RNA ISH and 
ICC staining, the correlation of positive signals from RNA ISH 
FigUre 3 | rna ish specificity test. RNA ISH specificity test with DAPI, CK 8, 18, 19-type 4, HER2 sense/anti-sense probes, and EGFR sense/anti-sense 
probes. The parallel stained cells are the NME cells from healthy donor spiked with BT474 cells at a ratio of 4:1 in cell number. (1)–(4) are the slide with DAPI, CK 8, 
18, 19-type 4, EGFR-type 1; (5)–(8) are the slide with DAPI, CK 8, 18, 19-type 4, sense-EGFR-type 1. (9)–(12) are the slide with DAPI, CK 8, 18, 19-type 4, 
HER2-type 6. (13)–(16) are the slide with DAPI, CK 8, 18, 19-type 4, sense-HER2-type 1.
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and fluorescent ICC staining was tested. Specifically, both cell 
surface proteins and the corresponding mRNAs were targeted 
and stained on the same cell with integrated RNA ISH and ICC 
staining. Figure 6A presents the staining of DAPI, EGFR anti-
body (ICC), EGFR-type 1 (RNA ISH), and HER2-type 6 (RNA 
ISH) on a mixture of normal blood cells and BT474 cells (ratio of 
4:1). Blood cells show no signal, while all BT474 cells are weakly 
positive on both EGFR fluorescent ICC staining and EGFR RNA 
ISH. Figure 6B presents the staining of DAPI, HER2 antibody 
(ICC), EGFR-type 1 (RNA ISH), and HER2-type 6 (RNA ISH). 
Overall, BT474 cells in Figure 6B have higher intensity of HER2 
signals than those from EGFR in both RNA ISH and ICC stain-
ing. The low positivity of EGFR and high positivity of HER2 in 
BT474 cells from the integrated RNA ISH and ICC staining are 
in accordance with the previous research (29). Furthermore, in 
Figure 6B, BT474 cells exhibit different levels of HER2 positiv-
ity in both RNA ISH and ICC staining.
rna ish with icc staining – Viral Targets
Having verified the robustness of the incorporated RNA ISH and 
ICC staining on some prevailing tumor markers, we extended 
the application to tumor markers of different categories, includ-
ing viral targets (this section) and enzymatic targets (next 
section). HPV16 infection is associated with the basal cells 
of the stratified epithelium and found in some specific types 
of cervical and head and neck cancers (30–32). Among the 
eight genes related to HPV16, E6/E7 oncogenes are associated 
with anti-apoptotic properties of HPV infection, while the 
corresponding proteins, E6/E7 proteins, are commonly used 
to signify the presence of HPV. To test the practicability of 
FigUre 4 | integrated rna ish and icc staining on her family markers. Integrated RNA ISH and fluorescent ICC staining with customized conjugated 
CK-AF488 antibody and EGFR-type 1, HER2-type 6, RNA ISH. (a) is BT474 cells, and (B) is the NME cells from blood specimen of colon cancer patient. CK+, 
EGFR+, and HER2+ cells are found among the NME cells in the staining.
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applying our incorporated RNA ISH and ICC staining on viral 
targets, a staining pattern of DAPI, CK-AF488 (ICC), HPV16 
E6/E7-type 1 (RNA ISH), and EGFR-AF647 (ICC) was used 
on HPV-positive and -negative cell lines. Figures  7A,B are 
representative images from the staining of SCC90 and SCC47 
cells mixed with normal blood cells (ratio of 1:4), respectively. 
In the RNA ISH channel of HPV16 E6/E7, the SCC47 cells have 
fewer dots (less than 10 dots per cell) than SCC90 (10–100 
FigUre 5 | integrated rna ish and icc staining on hedgehog pathway markers. RNA ISH staining with Smo-type 1 and Gli1-type 6. (a) is the RNA ISH 
staining of T47D cell line with CK 8, 18, 19-type 4, Smo-type 1, and Gli1-type 6. (B) is the integrated RNA ISH and fluorescent ICC staining with CK-AF488 (ICC), 
Smo-type 1 (RNA ISH), and Gli1-type 6 (RNA ISH) on the NME cells from a breast cancer patient. CK+, Smo+, and Gli1+ cells are found among these NME cells in 
the staining.
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FigUre 6 | integrated rna ish and icc staining consistency test. RNA ISH with fluorescent ICC staining with EGFR, HER2 antibody, and EGFR, HER2 RNA 
ISH on blood cells spiked with BT474 cells at a ratio of 4:1 in cell number. (a) is the staining of DAPI, EGFR-AF488 (ICC), EGFR-type 1 (RNA ISH), and HER2-type 6 
(RNA ISH). (B) is the staining of DAPI, HER2-AF488 (ICC), EGFR-type 1 (RNA ISH), and HER2-type 6 (RNA ISH).
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dots per cell). The observation is consistent with the results 
from RT-PCR and other studies, indicating that SCC90 is 
more positive than SCC47 in HPV16 (33, 34). Meanwhile, 
this staining pattern was also extended to patient samples. 
Figure  7C shows the parallel stained NME cells from head 
and neck cancer patients diagnosed with HPV-positive solid 
tumors. As an extended negative control, Figure  7D presents 
the staining with the same pattern and protocol as that applied 
FigUre 7 | integrated rna ish and icc staining on hPV markers.
(Continued)
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in Figures  7A–C, on blood cells spiked with BT474 cells, an 
HPV-negative breast cancer cell line. The negative results in 
HPV16 E6/E7 channel in BT474 cells are a further check on 
the specificity of the HPV16 E6/E7 RNA ISH probes.
rna ish with icc staining – enzymatic 
Targets
Labeling non-structural or membrane bound proteins, such 
as enzymes, in CTCs, is challenging for ICC staining, for a 
FigUre 7 | continued.  
Integrated RNA ISH and ICC staining with customized conjugated CK8, 18, 19-AF488 antibody (ICC), HPV16 E6, E7-type 1 (RNA ISH), and EGFR-AF647 antibody 
(ICC). The HPV16 E6, E7-type 1 probe is the 1:1 mixture of HPV16 E6-type 1 and HPV16 E7-type 1. (a,B) presents the staining of blood cells spiked with SCC90 
(a) or SCC47 (B) cells at a ratio of 4:1 in cell number. (c) shows the staining of the NME cells from head and neck cancer patients. Among these NME cells shown 
in (c), HPV+, EGFR+, CK+, or CK− cells are found. (D) is a specificity test with the staining of blood cells spiked with BT474 cells at a ratio of 4:1 in cell number. 
Both BT474 cells and blood cells are negative on HPV. The specificity of this test is hence proved.
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FigUre 8 | rna ish test on enzymatic targets. Integrated RNA ISH and ICC staining on enzymatic targets. Integrated RNA ISH and fluorescent ICC staining 
with customized conjugated CK8, 18, 19-AF488 antibody (ICC), EGFR-type 1 (RNA ISH), and PRMT5-type 6 (RNA ISH). (a) represents the staining of leukocytes 
spiked with MCF-7 cells at a ratio of 4:1 in cell number. The MCF-7 cells show low positive on PRMT5 and positive on CK and EGFR, while leukocytes are negative 
on all of them. (B) shows the staining of the NME cells from an esophageal cancer patient blood. PRMT5+ cells are found in this staining.
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number of reasons, including the mobility of the proteins 
after cell membrane permeabilization, low protein expres-
sion level, and low specificity of antibodies. Protein arginine 
methyltransferase 5 (PRMT5), a Type II arginine methyltrans-
ferase, which has been reported to be involved in the regulation 
of multiple tumorigenesis pathways, usually can only be stained 
13
Wu et al. Multiparameter Analysis of CTCs
Frontiers in Oncology | www.frontiersin.org November 2016 | Volume 6 | Article 234
by immunohistostaining on tumor biopsy (35, 36). With the 
high amplification of RNA ISH and high binding specificity 
between complementary oligonucleotides, RNA ISH may have 
the potential to visualize tumor-related enzymatic proteins in 
CTCs. Figure  8A presents images of blood cells spiked with 
MCF-7 at a ratio of 4:1 that were stained for CK-AF488 (ICC), 
EGFR-type 1 (RNA ISH), and PRMT5-type 6 (RNA ISH). In 
Figure 8A, normal blood cells are negative for CK, EGFR, and 
PRMT5, while MCF-7 cells are positive for EGFR and weakly 
positive on PRMT5. Meanwhile, the same pattern was extended 
to the NME cells from the blood sample of an esophageal cancer 
patient, as presented in Figure  8B. In Figure  8B, one CTC 
is positive for all markers, while another cell is only weakly 
positive for EGFR.
DiscUssiOn
The integrated RNA ISH and fluorescent ICC staining enables 
a multimodality confirmation of the positive expression of 
specifically targeted markers at different levels, as opposed to 
relying on a single antibody clone with a reported reactivity to 
specific isoforms of the targeted proteins. As we demonstrated 
in the previous study, in the prevailing ICC staining, even target-
ing the very common hematopoietic surface marker, CD45, can 
produce significantly different results depending on the selected 
clone of antibody and even the manufacturer where the clone is 
procured (10). Considering the variation in binding specificity 
and reactivity in regular ICC staining, the integrated RNA ISH 
and ICC staining may provide a more comprehensive and robust 
tool for visualized analysis at single-cell level for CTC research.
Exploiting the advantages of RNA ISH, several recently pub-
lished studies on CTCs demonstrated the ability of RNA ISH to 
visualize and quantify epithelial markers, Wnt pathway markers, 
and CD45 (37, 38). In these studies, RNA ISH and fluorescent 
ICC staining were conducted on parallel slides. Consequently, 
while the presence of individual markers can be determined via 
these approaches, the heterogeneity of CTCs prevents the con-
clusive determination of various marker combinations on a cell-
by-cell basis. To eliminate the errors from CTC heterogeneity in 
parallel RNA ISH and fluorescent ICC staining, the integrated 
RNA ISH and fluorescent ICC staining provides a solution to 
get information from both RNA ISH and ICC staining on the 
same cells.
To further investigate the specificity and selectivity of our 
RNA ISH technology, various combinations of cell types, probes, 
antibodies, and targeting markers were tested in this research. 
Unlike antibodies that frequently have low level of non-specific 
binding, especially on blood samples, we did not observe any 
positive signals in the cell types that were assumed to be negative 
for the specially targeted RNA ISH probes. The sense controls 
presented in Figure  3 further confirmed that the RNA ISH 
probes were highly selective and specific. The high specificity of 
RNA ISH was also supported by Figures 4–8 in which no RNA 
ISH-positive signal was detected from the blood cells that were 
present, either through spiking or in the case of patient samples, 
from the blood cells that made through the magnetic depletion 
step. As a further demonstration of the specificity of the RNA ISH 
staining, Figures 6A,B demonstrated that the cells stained with 
the antibodies targeting EGFR or HER2 were also positive with 
the RNA ISH targeting the appropriate mRNA; meanwhile, the 
blood cells spiked with the cell lines were negative for both the 
antibodies and RNA ISH.
The RNA ISH technology in this study creates a signal amplifi-
cation tree using branched single-stranded DNA. This amplifica-
tion tree can provide 400 binding sites for each labeling probe 
binding to single target sequence on mRNA. Several fluorescent 
molecules can be bound to each binding site and thus achieve 
a theoretical 8000-fold amplification for each mRNA target 
sequence bound. It has been reported that the high selectivity and 
high amplification levels in this RNA ISH probe design enable 
the tracking of single transcript of target mRNA or microRNA, 
as well as the quantitative analysis of the transcription level of 
the targeting gene. This quantitative analysis is precise enough 
to create a dynamic profile on the synthesis, transportation, and 
degradation of the nascent mRNAs after a chemical induction on 
the transcription of the corresponding targeted gene (19). Some 
later reports developed a computational identification procedure 
with multiple, singly labeled probes to count the RNA transcripts 
automatically (39). Here, in this study, we have not yet determined 
how many mRNAs correspond to each bright spot, which is an 
ongoing focus in our laboratory.
Despite the merits and superiority of RNA ISH over ICC 
staining in specificity, reactivity, and quantitation as discussed 
above, ICC staining, which targets proteins, may provide more 
direct information of CTCs since protein is the functional unit in 
most signal pathways. In the common practice of tumor cell line 
analysis, RNA ISH and ICC staining are applied to support each 
other on parallel slides from the same batch of cells of certain 
tumor cell lines. However, we suggest that unlike the relatively 
homogeneous tumor cell lines, the highly heterogeneous CTCs 
require all staining markers in all staining methods on the same 
cells. Our integrated RNA ISH and ICC staining can fulfill this 
challenging requirement and provide an analytical method for 
comprehensive visualized labeling on different markers in tumor-
related pathways.
A challenge with this RNA ISH technology combined with 
ICC is exposure time. Since for a specific marker, the amount of 
mRNA is usually lower than the amount of the corresponding 
protein, the signal from RNA ISH is usually weaker (although 
presumably more specific and precise) than that from ICC stain-
ing. Correspondingly, the camera exposure time for RNA ISH 
staining under the fluorescent microscopy scanning is about 
5–20 times longer than that for ICC staining. Hence, in a visual-
ized fluorescent characterization of the enriched CTCs which 
inevitably have some healthy, irrelevant cells, the automated 
fluorescent microscopy scanning takes 5–20 times longer to 
detect and analyze the target cells on the slides with RNA ISH 
staining than those with ICC staining. One solution in using an 
integrated RNA ISH and ICC staining protocol might consist of 
an automated fluorescent microscopy scanning system to quickly 
search the tumor-related target cell populations by ICC staining. 
Once identified, these targeted cells could then be analyzed for 
RNA ISH staining. This is part of the reason why the selection of 
the ICC markers in our integrated RNA ISH and ICC staining are 
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For the ease of the access and better resolution in our cur-
rent presentation, instead of confocal imaging which typically 
uses laser light, we chose to use a traditional epi-fluorescence 
microscope with excitation and emission filters, dichroic mirrors, 
and an intensified mercury bulb. This approach requires longer 
exposure time, accompanied with the increased potential of 
the signal “leaking” from the other ICC dyes into the RNA ISH 
channel. For example, it is suggested that weak and diffuse orange 
color in the EGFR-type 1 images in Figures 6A,B is leakage from 
the AF488 signals, but not the actual RNA ISH signals which are 
typically observed as bright spots (i.e., Figure 2). To address this 
issue, future studies will use a Nuance spectral deconvolution 
system, which allows the “leaking signals” to be subtracted from 
the corrected images.
In some images from RNA ISH slides (i.e., Figure 6), despite 
the careful optimization on the fixing time with 4% paraformal-
dehyde and protease treatment, bright spots indicating positive 
signals can be observed outside of the cells. Initially, these outly-
ing spots were regarded as non-specific binding to background 
impurities. However, in the staining of both sense/anti-sense 
controls (Figure  3) and BT474 cells which serve as negative 
control for E6/E7 staining of HPV16 infected cells (Figure 7D), 
there were no bright spots near tumor cells. One hypothesis for 
these positive spots outside of the cells is the leakage of mRNA 
fragments. The RNA ISH staining protocol requires intensive 
permeabilization to facilitate the delivery of nucleic acid probes, 
amplifiers, and fluorochromes across the cell membrane. Thus, 
it is possible that some cell contents leak out of cells during the 
permeablization step. Another hypothesis is that these bright, 
extracellular spots are extracellular vesicles. The extracellular 
vesicles secreted from some cancer cell lines have been found to 
contain many tumor-related mRNA sequences via RT-PCR and 
RNA microarrays (40, 41). Further work is needed to examine 
the hypotheses and better understand the phenomenon.
cOnclUsiOn
The research aims to provide a robust separation and characteri-
zation method for heterogeneous CTCs. The CTCs were initially 
enriched by our NME process, in which all blood cells were 
concentrated and labeled with CD45 antibody that is conjugated 
with magnetic beads. The labeled cells then flowed through 
our customized QMS system where the non-hematopoietic 
cells without CD45-magnetic beads labeling were enriched. 
To compliment prevailing ICC staining, we introduced RNA ISH 
into our CTC characterization method and evaluated its specific-
ity and sensitivity. Furthermore, the integrated RNA ISH and 
ICC staining was developed to allow visualized multiparameter 
analysis at both RNA and protein levels.
The integrated RNA ISH and fluorescent ICC staining provides 
an approach to study the heterogeneity of CTCs by incorporating 
the strengths of antibody labeling and RNA ISH. To verify the 
practicability and robustness of this integrated staining, tumor 
markers of different categories, including epithelial markers, 
HER family markers, Hedgehog pathway markers, viral markers, 
enzymatic markers, etc., were tested on both cell line and NME 
cells from healthy donors and patients.
Currently, in our lab, the high expressing or well-studied 
tumor markers are stained with ICC staining, which has higher 
signal intensity, to shorten the duration of automated detection 
of CTCs. Meanwhile, RNA ISH is applied on novel markers to 
perform visualized, specific, and precise detection. The ongo-
ing work in our laboratory is focused on the use of spectral 
deconvolution technology not only to sharpen the images for 
each fluorescent signal but also to extend the number of targets 
stained with both ICC and RNA ISH technology up to seven 
distinct markers as well as the detailed quantitative evaluation of 
the staining results.
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